https://www.selleckchem.com/JAK.html
84, p=0.003). However, the incidence of central nervous system (CNS) progression was not associated with PD-L1 positivity, with a two-year cumulative CNS progression rate of 26.3% and 28.4% in PD-L1-positive and PD-L1-negative patients, respectively (log rank p=0.944). Furthermore, positive PD-L1 expression did not affect CNS progression or overall survival in patients with synchronous brain metastasis (long rank p=0.513 and 0.592, respectively). Initial brain metastases are common in NSCLC patients with positive PD-L1 expression. Further studies ar
Like
Comment
Share
